PDUFA III Deal Includes Risk Management Fees In “Peri-Approval” Phase
This article was originally published in The Tan Sheet
Executive Summary
The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years
You may also be interested in...
White House Eyes Ophthalmologist Roberts For FDA; Frist Is Sponsor
White House interest in Cornell ophthalmologist Calvin Roberts, MD, indicates that the search for a permanent FDA commissioner is continuing
FDA Protocol Reviews Would Include Outside Consultants Under PDUFA III
The PDUFA III agreement between FDA and industry includes a provision that would allow sponsors to request the participation of outside consultants in protocol design meetings
PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”
Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures